Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Harbor vs Immortals

Harbor
Graded #86

Higher grade

vs+10.200000000000003
Immortals
Graded #284

Lower grade

The verdict

Harbor takes it — 72/100 to 61.8/100.

Harbor grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Harbor is a physician-led telehealth platform offering compounded semaglutide (from $99/mo) and compounded tirzepatide (from $149/mo) — among the lowest headline prices in the market.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHarbor +20
74
54
Dose & formulationEven
64
64
Clinical oversightHarbor +1
89
88
Labs & monitoringHarbor +9
63
54
FulfillmentHarbor +13
81
68
Contract termsHarbor +27
47
20
Harbor · left barImmortals · right bar

The numbers

MetricHarborImmortals
WeighScore72/10061.8/100
GradeCC
Scorecard rank#86#284
Semaglutide$99/mo (starting dose, compounded)$167/mo (microdose tier, compounded)
Tirzepatide$149/mo (starting dose, compounded)$180/mo (microdose tier, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Harbor

Graded #86 · C

Strengths

  • Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
  • LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
  • 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
  • 12-Month Money Back Guarantee if you don't reach your weight-loss goal
  • HSA/FSA eligible; no hidden fees, no insurance billed

Where it loses points

  • Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
  • Dietitian support offered only post-program (maintenance phase), not during active treatment
  • State-specific consultation types vary; nationwide availability unconfirmed for all states
  • No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
  • Newer brand; success rate and member counts are on-site claims, not third-party verified
Immortals

Graded #284 · C

Strengths

  • LegitScript certified (ID 50458743) with board-certified U.S. physician review within 72 hours
  • Physician consult + prescription bundled in price — 'You pay for treatment. That's it' with no added fees
  • Competitive pricing: semaglutide microdose from $167/month, tirzepatide from $180/month (promotional)
  • Unlimited provider messaging for 12 months included; video consults available
  • Founded by Bryan Johnson and Kate Tolo; clinical lead Dr. Carl Seger, M.D. (preventive/longevity medicine)

Where it loses points

  • Microdose framing uses sub-clinical doses — lower weight-loss efficacy than standard GLP-1 protocols
  • Quarterly commitment only — 3-month minimum, paid upfront ($501–$540/quarter); no monthly flexibility
  • State availability not publicly listed; 'eligible U.S. states' with no specific state list
  • Labs not included; baseline bloodwork protocol not disclosed on any public page
  • Compounding pharmacy not named; no 503A/503B accreditation details disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard